GlassScriptPhysician profile
Hector Lozano
NPI 1619083680
$27,967.67
in general payments reported to CMS, 2019-2025
15 companies · $3,502 in 2025
The $3,502 reported for 2025 was more than what 88% of Gastroenterology (Internal Medicine) providers received nationally (typical 2025 total: $636).
See the full distribution for Gastroenterology (Internal Medicine)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $4,630 · 2020: $2,462 · 2021: $574 · 2022: $10K · 2023: $4,852 · 2024: $1,450 · 2025: $3,502.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $3,456 · Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $3,182 · Food and Beverage: $2,416 · Compensation For Serving As Faculty Or As A Speaker For A Medical Education Program: $750.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $3,456.25 |
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $3,182.40 |
| Food and Beverage | $2,415.77 |
| Compensation For Serving As Faculty Or As A Speaker For A Medical Education Program | $750.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| E.R. Squibb & Sons, L.L.C. | $14,390.59 | 2021-2025 | Zeposia |
| Pfizer Pharmaceuticals LLC | $4,471.11 | 2019-2020 | |
| Abbvie INC. | $4,113.94 | 2019-2025 | |
| Merck Sharp & Dohme LLC | $1,723.33 | 2019-2020 | |
| Celgene Corporation | $1,200.00 | 2023-2024 | Zeposia |
| Janssen Pharmaceuticals, INC | $1,158.41 | 2019-2025 | Stelara, Tremfya |
| Pbg Puerto Rico LLC | $298.76 | 2019-2025 | |
| Cvrx, INC. | $186.26 | 2024-2025 | Barostim Neo System |
| Takeda Pharmaceuticals U.S.A., INC. | $137.30 | 2019-2025 | Entyvio |
| Janssen Biotech, INC. | $74.99 | 2020 | |
| Gilead Sciences, INC. | $70.95 | 2020-2024 | |
| Organon LLC | $62.86 | 2023 | Renflexis |
| Madrigal Pharmaceuticals | $29.17 | 2025 | Rezdiffra |
| Eli Lilly Export S.A. Puerto Rico Branch | $25.00 | 2025 | |
| Exact Sciences Corporation | $25.00 | 2025 | Cologuard Collection Kit |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Hector Lozano listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.